PRAGMATICA-LUNG / S2302 — Ramucirumab plus pembrolizumab versus standard care in previously treated NSCLC

Phase 3 · Non-Small Cell Lung Cancer

Population

Stage IV or recurrent NSCLC progressing after prior immunotherapy and chemotherapy.

Primary Endpoint

Overall survival

Rationale

A phase 2 signal suggested ramucirumab plus pembrolizumab helps after progression on immunotherapy. PRAGMATICA-LUNG uses a streamlined design to confirm the benefit in a real-world population and to test whether pragmatic trials can deliver answers faster and more inclusively.

What It Could Change

Could validate a post-immunotherapy treatment option and a faster, more inclusive model for running practical trials.